Ozempic is paving the way for other GLP-1 drugs to treat conditions beyond kidney disease The FLOW trial results, along with the recent announcement that Wegovy is approved to reduce cardiovascular risk in people with obesity, are the latest indications that these drugs have benefits for conditions beyond their original intended treatment of type 2 diabetes
Slower escalation options Some providers extend the escalation timeline, keeping patients at each dose level for 6 to 8 weeks instead of 4
For the full surgical cost breakdown, see our bariatric surgery cost without insurance guide
Methylcobalamin/Semaglutide and Cyanocobalamin/Tirzepatide can be part of a broader plan that includes dietary changes, exercise, and other therapies
You can view the entire study directly in Truveta Studio
The study, conducted by researchers in the US and Brazil, focused on the use of Ozempic in treating metabolic dysfunction-associated steatotic liver disease, or MASLD: the most common cause of chronic liver disease and of liver-related deaths
